Jake Mazan
The pharmaceutical industry has faced well documented challenges over the last 12 months, such as the Pfizer. The industry is only too aware of this and understands that now is the time to look at new processes and a change in the way they have traditionally done business.
Christopher R Albani,
Managing Director, Yorozu Tabata, Partner, PRTM Management Consultants, Japan
During the last few years, pharmaceutical companies have shifted their focus in Pharmacovigilance operations from "compliance" to "productivity". In the midst of the current economic crisis, this tendency seems obvious. However, another trend is emerging. Some leading firms have turned their functional strategies in this area from "productivity of operation" to "strategic value of safety profiles.
Satish Totey Chief Scientific Officer, Stempeutics Research Pvt. Ltd
Stem Cells have been repeatedly talked in public and scientific community and all the stem cell biologists and scientists agree that stem cell have the potential for treating human diseases and disorders.
George YehGeneral Manager, Taiwan Liposome Company
The pharmaceutical industry is in a nascent stage of globalisation in terms of drug development, where a few big names still reign. . Yet an increasing trend of transnational partnerships is seen to be formed to deliver value arbitrage through leveraging cost arbitrage. How the Asian biotechnology companies take advantage of this trend has become the vital topic for all managers involved.
Timothy Stockert, Principal & Owner, INNOVA Group, Inc. USA
As increased competitiveness paves its way in the global arena, all market places, whether pharma, automotive or manufacturing are undergoing continual changes to cut cost and increase efficiency. This article brings with it the challenges faced by individual companies to tailor their project managements and stay ahead of the competition.
Dr John Favier, Chief Executive Officer, DEM Solutions, United Kingdom
Efficient handling and processing of particulates is critical to profitable manufacture of pharmaceutical products. Over 75 percent of all pharmaceutical products are in the solid dosage form and particulates are involved in almost every stage of the manufacturing process.
Susan Bassion,CDISC Lab Team Leader, CDISC, USA
Establishing a good relationship between a sponsor and a contract research organisation (vendor) is the responsibility of both the sides in the partnership. Sponsor accessibility and responsiveness is a critical piece of the solution. The vendors, in turn, must meet their obligations in a professional manner.
Jim Worrell,CEO, Pharma Services Network
The BioPharm market is being driven by strong governmental support, including the creation of intellectual property protection laws, economic development zones, and relevant university curriculum.
Sandra Fox, President, HighTech Business Decisions
Pricing pressures, primarily for large-scale production of biologics is causing the typically North American and European industry to now include Asia.
Michael J. Rieder,Chair in Paediatric Clinical Pharmacology, Children’s Health Research Institute, Schulich School of Medicine & Dentistry, University of Western Ontario
Regulatory imperatives, economic incentives, new methods and technology and the chance to make a difference in the health of children worldwide provide compelling reasons to pursue global drug studies in children.
Mary Dunkle, Vice President, Communications, National Organization for Rare Disorders
As the home to more than half the world’s population, Asia is poised to become an area of tremendous interest to pharmaceutical and biotechnology companies engaged in research on the thousands of diseases considered rare.
Yuta Kaneko, Director, Meditech, ACNielsen
Understanding the psyche of Japanese pharmaceutical consumers is really a case of understanding the psyche of older and elderly Japanese.
Liew Kou Yew, Assistant Vice President, Life Sciences - Asia, Rabobank International
Given its traditional resourcefulness and determination, it is beyond doubt that Asia’s place within the global pharmaceutical industry over the next few decades will grow in rapid prominence.
C R Chenthir K, CEO, Plutus Pharma Network Pvt. Ltd.
Increasing patent expirations, Asia's aging population and the need for less expensive drugs is fuelling the growth of generics market in the region. However, there are some challenges to be met in order to sustain the growth.
Rajeshwer ChigullapalliandFeroz ZaheerEditorial Team, Pharma Focus Asia
Asia is emerging as a powerhouse of pharmaceutical R&D facilitated by the availability of a vast patient population, quality data, lower costs and skilled manpower.